This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Genomic sequencing is a window into our genetic makeup. The GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, recently published in the Journal of the American Medical Association (JAMA) , highlights how adding genome sequencing to newborn screening could reshape early detection for rare genetic conditions.
Canary Wharf’s bid to become a new hub for the lifesciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development. facility dedicated to a combination of wet lab and office space, revealed in March, intended as a focal point for lifesciences companies in London.
The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance lifesciences.
The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.
– A Purdue Foundry-affiliated company with a growing reputation as a search engine for genome sequence data in lifesciences has joined a nationally ranked health care startup accelerator. Credit: Karyosoft/Rajesh Perianayagam WEST LAFAYETTE, Ind.
Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. The post The use of genomic profiling testing to improve oncology care appeared first on.
GSK has entered a strategic partnership with Wave LifeSciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.
27, Vilnius will host the EFIB’2022 event which will bring the European lifescience sector together. In the field of lifesciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.
From the Human Genome Project to contemporary drug development, collaboration is critical to the lifesciences. It is also an important factor in the success of lifesciences clusters, where a high concentration of pharmaceutical or medical device companies can all be found in one district, city or region.
With the huge abundance of genomic data generated from lifescience experiments, processing large datasets remains a challenge in the field of bioinformatics.
This episode features an interview with Dr. Asaf Zviran, CEO and co-founder of C2i Genomics, a biotech company focused on improving cancer detection and monitoring using genomics- and AI-based approaches. Zviran’s founded C2i Genomics, including a personal story, and how the company is focused on truly personalizing cancer treatments.
As we step into 2024, the lifesciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. These companies are at various stages of research and clinical trials.
For more information on tackling this “genomic analysis bottleneck,” watch this on-demand webinar. HS: Due to the heterogeneity of the rare disease population, there are many relevant gene lists, and the genomic data analysis of these patients covers almost 2,000 different genetic targets.
Subscribe to the Xtalks LifeScience Podcast to never miss a new episode. It leverages various patient-specific factors, including genetics, age, weight, organ function and even lifestyle, to determine the most appropriate dosage for each individual.
How did you get into lifesciences? After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, LifeScience and Healthcare. What has your career path been? Ultimately, this has to start at school.
ERS Genomics and G+FLAS LifeSciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS LifeSciences sign CRISPR/Cas9 license agreement G+FLAS LifeSciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →
Biopharma and lifesciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
BARCELONA/LONDON, 25.05.23: Seqera Labs, the leading provider of secure workflow orchestration software in the lifesciences sector, has partnered with Genomics England, the government-owned company that launched the 100,000 Genomes Project in partnership with the NHS.
Nashville Biosciences and Illumina Announce Agreement to Establish Preeminent Clinico-Genomic Resource for LifeSciences Research & Development Nashville Biosciences and Illumina Announce Agreement to Establish Preeminent Clinico-Genomic Resource for LifeSciences Research & Development NASHVILLE, Tenn.–(BUSINESS
(NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
Lee Honigberg on the Future of Blood-Based Biomarker Assays GeneDX GeneDX recently integrated AI (Multiscore) into its interpretation platform, improving speed and accuracy in analyzing complex genomic data. 10x Genomics 10x Genomics reported $707 million in 2024 revenue.
The up-and-coming field of spatial genomics in biology promises to bridge the gap between high plex, high throughput, and high resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players. 70+ spatial Genomics solutions are developed by industry and non-industry players. Concluding Remarks.
Illumina, the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a lifesciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
Illumina , the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a lifesciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations HERCULES, Calif.–(BUSINESS NYSE: BIO and BIOb), a global leader of lifescience research and clinical diagnostic products, … Continue reading →
However, developments in genomic medicine are making huge strides to improve this situation, and these will also be discussed during the webinar. Dr Joanne Hackett is the head of genomic and precision medicine at IQVIA and previously was chief commercial officer at Genomics England. About IQVIA.
Our colleague Matthew Herper joins us for a deep dive into Illumina, explaining how the biggest company in genome sequencing lost the faith of shareholders and painted itself into a corner.
27, Vilnius will host the EFIB’2022 event which will bring the European lifescience sector together. In the field of lifesciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.
The PING Conference 2022 is back in person this year, with opportunities to network face-to-face with people from right across the lifesciences ecosystem. Hear about how the UK is leading the way in what has been described as the ‘Golden Age for LifeSciences Innovation’ and the opportunities arising from this from leading experts.
Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows SAN DIEGO–(BUSINESS WIRE)–Crown Bioscience, a JSR Life (..)
HumGut comprises a collection of about 30,000 genomes, covering the broad diversity of bacterial genomes found in the human gut. This work is funded by the Norwegian University of LifeSciences (NMBU) and GA with support from the Research Council of Norway through an Industrial PhD program.
DeepMind partnered with the European Molecular Biology Laboratory (EMBL) to come up with the AlphaFold database, which predicts the three-dimensional structures of the human proteome – nearly all (98.5%) of the 20,000 or so proteins expressed by the human genome.
This involves the integrated analysis of several layers of biological data, including genomic, proteomic, transcriptomic and phosphoproteomic data using novel transomics technologies involving lab methods and AI approaches. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
Eterovic brings much knowledge and experience to the table, having led the development of a new Oncology Diagnostic program at Eurofins Viracor that integrates the latest genomic profiling techniques. Eterovic highlights that the financial and logistical barriers to comprehensive genomic profiling are high but not impossible to overcome.
John Finn, PhD Chief Scientific Officer Tome Biosciences Dr. Finn has over 20 years of experience in the gene therapy space with a focus on genome editing and delivery technologies. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
The move follows the 2019 merger between Caprion and HistoGeneX , a Belgian histopathology and genomics lab. While Caprion-HistoGeneX’s name change to CellCarta kicked off 2021, it followed a trend of lifescience companies rebranding that started last year.
CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome. It is difficult to control where the viral vectors insert genes in the genome, and it is difficult to manufacture large quantities of clinical-grade viral vectors. From the Bench to Patient Therapeutics.
It was found that the gene being delivered through the therapy had integrated into the genomes of six of the seven mice that were administered the highest dose. Although a rare event that occurs at very low frequency, AAV vectors can integrate into genomes through homologous recombination.
The team debates the ethical considerations around epigenetic therapies and genome editing, and how scientific communications should be improved to help educate the public on complex medical breakthrough. Subscribe to the Xtalks LifeScience Podcast to never miss a new episode.
As data and digital technology become vital to every aspect of lifesciences, the industry is increasingly looking beyond biologists, chemists, and doctors to drive its drug development – and finding that technology has a chief role to play in the future of medicine. on Big data: astronomical or genomical? ,
The CRISPR-Cas9 gene editing system uses a programmable single guide RNA sequence (sgRNA) to find and bind to specific regions of DNA and the Cas9 nuclease induces double strand breaks at these target regions of the genome. An RNA strand guides Cas9 to cut at a particular genomic site and insert the landing site, which is 46 DNA base pairs.
There have been great strides made in genomics to refine tools that determine the safest, most effective course of treatments for patients across a number of disease states. Looking at an individual’s genomic profile also provides an understanding of appropriate medication dosage.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content